Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) Q2 2023 Q2 2023 Earnings Call Transcript July 25, 2023 8:30 AM ET

Company Participants

Rachel Frank - Associate Director of Investor Relations

Sanj Patel - Chief Executive Officer

Ross Moat - Senior VP & Chief Commercial Officer

Eben Tessari - Chief Operating Officer

Mark Ragosa - Senior VP & CFO

John Paolini - Senior VP & Chief Medical Officer

Conference Call Participants

Anupam Rama - JPMorgan

Paul Choi - Goldman Sachs

Alexandria Hammond - BofA

David Nierengarten - Wedbush Securities

Liisa Bayko - Evercore ISI

Operator

Good day, and thank you for standing by. Welcome to the Kiniksa Pharmaceuticals Second Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers presentation there will be a question and answer session. [Operator Instructions] Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speaker today, Rachel Frank, Head of Investor Relations.

Rachel Frank

Thank you, operator. Good morning, everyone, and thank you for joining Kiniksa's call to discuss our second quarter 2023 financial results and recent portfolio execution.

Highlighting these results can be found on our website under the Investors and Media section.

As for the agenda, our Chief Executive Officer, Sanj Patel, will start with an introduction. Ross Moat, our Chief Commercial Officer, will provide an update on our outlet local execution. Then Mark Ragosa, our Chief Financial Officer, will review our second quarter 2023 financial results. And finally, Sanj return for closing remarks and will kick off the Q&A session, in which Eben Tessari, our Chief Operating Officer; and John Paolini, our Chief Medical Officer, will also be on the line.

Before getting started, please note that we will be making forward-looking statements today that are subject to risks and uncertainties that may cause actual results to differ materially from these statements. Our review such statements and risk factors can be found on this slide as well as under the caption Risk Factors taking in our SEC filings. These statements speak only as of the date of this presentation, and we undertake no obligation to update such statements, except as required by law.

With that, I will turn it over to Sanj.

Sanj Patel

Thanks, Rachel, and good morning, everyone. I'm happy to review our second quarter 2023 financial results today. We've continued to execute across our cardiovascular and autoimmune franchises, positioning us for success and growth in 2023. On the commercial side, Q2 represented another quarter of growth for with a net product revenue of $54.5 million.